JPRN-jRCT1051230031招募中2 期
Sequential Strategy Based on Endocrine Therapy after CDK4/6 Inhibitor in patients with HR-positive HER2-negative locally advanced or metastatic breast cancer : A Randomized Multicenter Phase II trial
Takahiro Nakayama0 个研究点目标入组 150 人开始时间: 2023年6月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •Patients with HR-positive/HER2-negative locally advanced or metastatic breast cancer resistance to first-line therapy with endocrine therapy and CDK4/6 inhibitors.
排除标准
- •Patients with past history of ILD during the first line therapy
研究者
相似试验
进行中（未招募）
1 期
Optimizing endocrine treatment > 5 years after surgery for breast cancer patients: a registry-based randomized clinical trialBreast cancerCTIS2023-506135-14-00Region Oerebro Laen3,832
招募中
2 期
SEQUence of Endocrine therapy in advanced Luminal Breast cancer (SEQUEL-Breast) A phase 2 study on fulvestrant beyond progression in combination with alpelisib for PIK3CA-mutated, hormone-receptor positive HER2 negative advanced breast cancer.HR positive/HER2 negative breast cancer10006291Breast cancerNL-OMON54330BOOG Study Center130
进行中（未招募）
1 期
SEQUEL-Breast: a phase 2 study on the combination of alpelisib and fulvestrant after progression on previous therapy with fulvestrant in patients with PIK3CA-mutated, hormone-receptor positive, HER2 negative advanced breast cancerPIK3CA-mutated, hormone-receptor positive HER2 negative advanced breast cancerMedDRA version: 24.0Level: PTClassification code 10085481Term: Hormone receptor positive HER2 negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10081234Term: PIK3CA-activated mutationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-004191-33-NLBOOG Study Center130
招募中
不适用
ocal treatment in addition to endocrine therapy in ER-positive/HER2-negative oligo-metastatic breast cancerKCT0003767Yonsei University Health System, Gangnam Severance Hospital110
进行中（未招募）
1 期
POETIC-A: PreOperative Endocrine Therapy for Individualised Care with Abemaciclibon-metastatic operable invasive ER+ HER2- breast cancer in post-menopausal womenMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003897-24-GBThe Institute of Cancer Research2,500